Study of tulisokibart for moderate to severe Crohn's disease
Part of Digestive system clinical trials.
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a Crohn's disease diagnosis for at least 3 months.
- Your Crohn's disease is moderate to severe.
- You have tried other treatments like steroids, immunomodulators, or biologics without enough success or you couldn't tolerate them.
- You are 16 years old or older (teens 16-17 may join if local rules allow).
- You do not have certain complications like abscesses, strictures, or prior surgery that would interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new targeted therapies for adults with moderate to severe Crohn's disease that hasn't improved with standard treatments. The goal is to see if these drugs can reduce inflammation and improve symptoms.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This study tests a new drug called duvakitug to see if it can help maintain improvement in people with moderate to severe Crohn's disease. It's for patients who have already responded to treatment in a previous study.
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.